Pyrazinamide resistance of novel mutations in and their dynamic behavior.

Pyrazinamide (PZA) is one of the essential anti-mycobacterium drugs, active against non-replicating (MTB) isolates. PZA is converted into its active state, called pyrazinoic acid (POA), by action of encoding pyrazinamidase (PZase). In the majority of PZA-resistance isolates, harbored mutations in the coding region. In our recent report, we detected a number of novel variants in PZA-resistance (PZA) MTB isolates, whose resistance mechanisms were yet to be determined. Here we performed several analyses to unveil the PZA mechanism of R123P, T76P, G150A, and H71R mutants (MTs) through molecular dynamics (MD) simulations. In brief, culture positive MTB isolates were subjected to PZA susceptibility tests using the WHO recommended concentration of PZA (100 μg ml). The PZA samples were screened for mutations in along sensitive isolates through polymerase chain reactions and sequencing. A large number of variants (GeneBank accession no. MH461111), including R123P, T76P, G150A, and H71R, have been spotted in more than 70% of isolates. However, the mechanism of PZA for mutants (MTs) R123P, T76P, G150A, and H71R was unknown. For the MTs and native PZase structures (WT), thermodynamic properties were compared using molecular dynamics simulations for 100 ns. The MTs structural activity was compared to the WT. Folding effect and pocket volume variations have been detected when comparing between WT and MTs. Geometric matching further confirmed the effect of R123P, T76P, G150A, and H71R mutations on PZase dynamics, making them vulnerable for activating the pro-drug into POA. This study offers a better understanding for management of PZA TB. The results may be used as alternative diagnostic tools to infer PZA resistance at a structural dynamics level.